Group 1 - The core viewpoint of the news highlights the active trading and significant inflow of funds into the Hang Seng Innovative Drug ETF (159316), indicating a growing interest in innovative drug investments in the Hong Kong market [1][2] - As of June 26, the latest scale of the Hang Seng Innovative Drug ETF reached 367 million yuan, with a total share of 292 million, both hitting record highs since its inception [1] - The recent issuance of the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines" by the National Medical Insurance Administration marks a significant step in integrating commercial health insurance into the multi-level medical security system [1] Group 2 - The report from Guosen Securities suggests that the large population of chronic disease and non-standard patients in China, coupled with the reform of medical insurance payment methods, indicates a long-term unmet medical demand [1] - The changing landscape of medical insurance payments is expected to enhance the supplementary role of commercial health insurance, presenting a stable development opportunity for the commercial insurance market in the medium to long term [1] - The Hang Seng Innovative Drug ETF closely tracks the Hang Seng Innovative Drug Index, which reflects the performance of Hong Kong-listed companies involved in the research, development, and production of innovative drugs [1][2]

伊朗方面说，美国的钻地弹只摧毁了部分附属设备，最核心的设备，完好无损。 后面修一修补一补，还能继续用。 01 整体趋势 过去的一周，全球资金都在关注一件事，那就是伊朗、以色列、美国三国之间的博弈。 似乎有愈演愈烈的趋势，但又拿不准。 搞的全球资金都陷入了一片迷茫。 比如，关于核设施到底有没有被摧毁，就有两个版本。 美国方面说，已经彻底摧毁了伊朗的核设施，彻底消除了核威胁。 你如果觉得伊朗方面的说法有可信度，就是毁掉了几个边边角角的设备而已。 那么，伊朗也不至于放狠话说每一名美国公民都是打击目标，更不至于说是要封锁霍尔木兹海峡。 如果觉得美国方面有可信度。 那么核心设施被摧毁，怎么说也能观测到地震，观测到放热，观测到核辐射吧。 而这些也都没有。 所以现在这件事就变成了，舆论上很激烈，后果上很严重，但是表现在资产价格上。 原油今天又是高开低走； 黄金高开后马上翻绿； 日经、大A低开高走，上证指数收盘大涨65个BP。 说明资金的预期也很割裂。 我觉得吧，对于这种重大不确定性的东西，我们有两个确定性的动作可以做。 第一，就是资产配置。 权益资产占比高的，可以将部分换成黄金，相当于两头堵，无论后续是升级了还是降温了，资 ...

把握创新药行情投资机遇，港股创新药ETF（513120）凭借三大优势成为资金布局首选：一是跟踪的中证香港创新药指数，其申万二级创新药企权重超过 91%，精准覆盖药明生物、信达生物等龙头企业；二是港股创新药ETF最新规模达125亿元，月内日均成交额超75亿元，规模、流动性均同类居首；三是 支持T+0交易，操作灵活。场外投资者可通过其联接基金（A类019670，C类019671）便捷布局。 展望后市，中泰证券指出，从基本面来看，创新药仍是当前医药板块中产业趋势最为明确且具备未来成长空间的子行业，我们认为全年维度创新药作为医 药板块的投资主线不会变化，短暂调整后板块有望在分化中持续上涨，在调整中建议坚守相对主流的优质创新药标的，以及将有BD或是数据催化的公 司。 EASY ETF 这样投资更简单! 发中证香港创新药ETF 513120 寫 港股创新药ETF 联接A: 019670 联接C:019671 6月以来，港股创新药板块持续成为市场焦点，交投持续活跃。以全市场规模最大的港股创新药ETF（513120）为例，截至6月23日，该产品连续10个交易 日持续获资金净买入，最新规模超125亿元，月内日均成交额超75亿元 ...

截至2025年6月19日 13:35，恒生创新药ETF(159316)盘中换手88.15%，成交2.91亿元，市场交投活跃。 截至6月18日，恒生创新药ETF(159316)最新规模达3.34亿元，创成立以来新高。恒生创新药 ETF(159316)最新份额达2.67亿份，创近1月新高。 恒生创新药ETF紧密跟踪恒生创新药指数，恒生创新药指数反映业务与创新药研究、开发及生产相关的 香港上市公司之表现。 恒生创新药ETF(159316)是目前市场上跟踪恒生创新药指数的唯一一支ETF产品，具备高弹性和稀缺 性，帮助投资者更好把握本轮港股创新药投资机遇。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 从资金净流入方面来看，恒生创新药ETF近6天获得连续资金净流入，合计"吸金"1.21亿元。 中国银河证券指出，2025年国内政策端全链条支持创新药发展，丙类目录即将落地，集采政策优化纠 偏，医保谈判逐步成熟。同时国内创新药企业基本面持续改善，海外BD规模再创历史新高，重磅交易 频繁刷新记录，国产创新药全球影响力持续攀升。宏观层面全球主要央行利率呈降息趋势，美联储进入 降息周期，行业投融资活跃度提 ...

Group 1 - Public funds in the pharmaceutical sector have shown significant excess returns, with an average net value growth rate exceeding 19% as of June 18, making it a market focus [1][3] - The average net value growth rate for all public funds is 2.83%, while over 260 pharmaceutical-related funds have achieved an average growth rate of 19.66%, indicating strong profitability [1][3] - Among the top 100 funds by performance, pharmaceutical funds occupy 49 positions, highlighting their strong earning effect [1] Group 2 - Funds specifically focused on "innovative drugs" have performed exceptionally well, with an average net value growth rate of 27.68%, and 21 funds exceeding 20% growth [3] - Key factors driving the strong performance of the pharmaceutical sector, particularly innovative drugs, include supportive policies such as improved drug procurement mechanisms and accelerated new drug approvals [3] - The period from 2025 to 2028 is critical for Chinese innovative drug companies to enter profitability, with 2025 being a pivotal year for the industry [3] Group 3 - Increased collaboration between domestic innovative drug companies and multinational pharmaceutical firms reflects the global competitiveness of China's innovative drug sector [4] - Fund managers are optimistic about the long-term investment value of the innovative drug sector, citing improved valuation post-adjustment and enhanced R&D efficiency due to domestic talent [3][4] - The government’s influence on drug procurement is diminishing, further supporting the growth potential of the innovative drug sector [3]

Group 1 - The Hong Kong innovative drug sector is experiencing a significant revaluation opportunity after over three years of downturn, with over 30 companies seeing their stock prices double since early 2025 [1] - Notable companies like Sihuan Pharmaceutical and Innovent Biologics have market capitalizations exceeding HKD 50 billion and HKD 120 billion respectively [1] - More than ten innovative drug companies have submitted listing applications to the Hong Kong Stock Exchange this year, with a record seven applications in the first half of June alone [1] Group 2 - The recent rise in the Hong Kong biopharmaceutical sector is primarily a valuation correction after previous significant declines, with some companies experiencing over 90% drop from historical highs [2] - Key players driving the market include companies like BeiGene and Innovent Biologics, which have achieved overseas commercialization through business development partnerships [2] - The investment cycle in the primary market is expected to take time to recover, as many institutions face tight funding and only a few top-tier institutions can sustain investments [2] Group 3 - The investment landscape is shifting, with early-stage projects attracting significant funding, while clinical and later-stage projects struggle to secure adequate financing [2] - The Hong Kong market's acceptance of companies in phase II clinical trials provides an important exit channel for the primary market [3] - Collaborations between multinational pharmaceutical companies and private equity firms to establish investment funds in the innovative drug sector are becoming more common [4] Group 4 - The core factor influencing the commercial value of innovative drugs is the healthcare payment policy, with recent trends in pricing negotiations becoming more favorable for companies [4] - Concerns exist regarding the potential negative impact of excessive cost control on research and development motivation within the industry [5] - There is a consensus among investors on the need for long-term capital support, with hopes for increased participation from insurance and social security funds [5] Group 5 - The investment trend for the second half of the year and into 2026 is expected to see a concentration of funds towards truly innovative companies, while projects lacking differentiation may be eliminated [5] - The global competitiveness of Chinese innovative drugs is improving, with a shift from imitation to original innovation, particularly in areas like bispecific antibodies and cell therapies [5]

Core Insights - 2025 is expected to be a transformative year for the innovative drug sector after four years of deep adjustments, with significant revenue growth anticipated for innovative drug companies [1][2] - The investment strategy of Ping An Pharmaceutical Select Stock Fund has yielded an impressive return of over 85% since its inception, outperforming similar indices by more than 70% [1] - The confidence in the innovative drug sector stems from the convergence of policy changes, international expansion, and profitability turning points [2] Industry Outlook - 2025 is projected to be the starting point for revenue growth, profitability, and valuation increases for innovative drug companies [2][3] - Approximately 80% of A-share and Hong Kong-listed innovative drug companies are expected to experience revenue growth following the 2024 medical insurance negotiations [2] - The period from 2025 to 2028 is critical for Chinese innovative drug companies as they are likely to enter a collective profitability phase [2] Policy and Market Dynamics - The introduction of multi-layered insurance payment mechanisms is a key variable for the long-term valuation uplift of innovative drugs [3] - The shift from a single basic insurance model to a dual-driven model of commercial insurance and basic medical insurance is expected to enhance the lifecycle and sales peak of innovative drugs [3] Investment Strategy - The investment approach prioritizes high-growth sectors, focusing on companies with favorable industry cycles, competitive landscapes, and robust business models [4] - The strategy includes selecting high-quality companies within high-growth sub-industries to capitalize on the benefits of a thriving market [4][5] - The focus is on avoiding downward policy cycles and seeking upward product cycles, leveraging unique advantages in the pharmaceutical sector [5] Specific Investment Opportunities - Key investment directions identified include bispecific antibodies, antibody-drug conjugates (ADC), targeted therapies, and autoimmune diseases [5][6] - The ADC sector is highlighted as a leading area for innovation, with a significant number of potential products in development [6] - The targeted therapy market is projected to grow significantly, with Chinese companies beginning to accelerate their market presence [6] - Autoimmune diseases are gaining attention, with the first domestic innovative drug expected to be approved soon, increasing market focus [6]

Core Viewpoint - The innovative pharmaceutical sector has shown significant recovery this year, becoming a popular investment area, with a peak in the number of new pharmaceutical-themed funds being reported in the second quarter of 2023 [1][2]. Fund Reporting Peak - Approximately 30 pharmaceutical-themed funds were reported in the second quarter of 2023, matching the total number of such funds expected to be established in 2024 [2]. - Fund companies are focusing on both index products and actively managed products, with several new ETFs and mixed funds being launched [2][3]. Investment Sentiment and Valuation - The investment sentiment in the innovative pharmaceutical sector is increasing, with many institutional investors showing strong interest [3]. - There are discussions regarding the valuation of the innovative pharmaceutical sector, with some experts suggesting that while current valuations are not low, they have not yet reached a bubble stage [4]. Market Dynamics and Future Outlook - The demand for pharmaceuticals is expected to rise due to an aging population, and the international standing of Chinese innovative pharmaceutical companies is improving [3]. - The innovative pharmaceutical sector is seen as a long-term investment opportunity, with expectations of increased business development and improved financial performance in the coming years [4]. Investment Strategy - Different fund companies are adopting varied strategies for participating in this investment opportunity, with a focus on active management potentially yielding higher returns in specialized sectors like innovative pharmaceuticals [5]. - The choice between passive and active products depends on the specific investment goals and the capabilities of fund managers [5].

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drug funds in the public fund rankings, driven by the pharmaceutical market, with a recommendation to seize investment opportunities in innovative drugs [1][2] - As of June 16, the average return of public funds is 3.16%, with stock and mixed funds yielding 3.64% and 4.5% respectively, while several pharmaceutical funds have significantly outperformed these averages [1] - Notable pharmaceutical funds include Changcheng Pharmaceutical Industry Selected Mixed Fund A with a return of 87.11% and Yongying Pharmaceutical Innovation Selected Mixed Fund A with 80.21% [1] Group 2 - The A-share pharmaceutical sector index has increased by 8.09% this year, while the innovative drug sector index has surged nearly 23%, indicating a robust market for innovative drugs [1] - Industry experts suggest that investors should focus on risk matching, valuation changes, and long-term planning when investing in innovative drugs [2] - Recent policy signals and a record number of innovative drug approvals in the first five months of the year indicate a favorable environment for the innovative drug sector, particularly in Hong Kong [2]

Core Insights - The innovative drug funds have emerged as the leading performers in the fund industry this year, with a significant number of fund managers heavily investing in this sector [3][4][5] - As of June 13, 2023, 63 funds have achieved over 50% returns, with 56 of them focusing on innovative drugs, representing nearly 89% of the top performers [3] - Notable fund managers such as Zhang Wei, Liang Furui, and others have shown exceptional performance by investing in innovative drugs, with some funds achieving returns exceeding 99% [5][6] Fund Performance - The top-performing funds include: - Huatai-PB Hong Kong Advantage Selection A (Zhang Wei) with a return of 99.50% - Great Wall Pharmaceutical Industry Selection A (Liang Furui) with 87.73% - Yongying Pharmaceutical Innovation Smart Selection A (Shu Kefa, Dan Lin) with 79.79% [3][5] - The performance of funds focusing on Hong Kong innovative drugs has been particularly strong, with significant interest in the STAR Market's innovative drugs as well [3][4] Fund Manager Strategies - Some fund managers, like Zhang Wei, have adopted a value investment approach and began investing in innovative drugs early, leading to substantial returns [5][6] - Zhang Wei's fund has a high concentration of holdings in innovative drug stocks, with a notable shift in focus beginning in Q1 2023 [6][7] - Other managers, such as Jin Xiaofei, recognized the potential of innovative drugs as early as Q4 2022 and have since adjusted their portfolios accordingly [8][9] Emerging Fund Managers - New generation fund managers like Liang Furui and Zheng Ning have quickly risen to prominence, with Liang's fund achieving a return of 87.73% and Zheng's fund reaching 79.30% [14][15] - Liang Furui's strategy focuses on disruptive innovation and companies with strong commercial potential, while Zheng Ning maintains a diversified portfolio across various pharmaceutical sectors [14][15][16] - The performance of these emerging managers highlights a shift in the fund management landscape, with younger managers capitalizing on new opportunities in the innovative drug sector [13][14]